Lupin Eyes 20% Growth Rate In U.S. From 110 Applications To FDA
This article was originally published in PharmAsia News
Executive Summary
Lupin is aiming for a 20% growth rate in the U.S. market, relying on approvals of many of the 110 drugs it has filed for approval by the FDA within the next four years, according to S Ramesh, President and CFO.
You may also be interested in...
UK Price Increases Add To Pharmacy Burden
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
QUOTED. 13 December 2019. Todd Garner
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Need a specific report? 1000+ reports available
Buy Reports